Latest Insider Transactions at Biolife Solutions Inc (BLFS)
This section provides a real-time view of insider transactions for Biolife Solutions Inc (BLFS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOLIFE SOLUTIONS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOLIFE SOLUTIONS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 08
2023
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
9,000
-7.02%
|
$225,000
$25.13 P/Share
|
|
Feb 08
2023
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+6.56%
|
$18,000
$2.06 P/Share
|
|
Feb 07
2023
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.83%
|
$25,000
$25.29 P/Share
|
|
Feb 07
2023
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+0.82%
|
$2,000
$2.06 P/Share
|
|
Feb 02
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.77%
|
$240,000
$24.43 P/Share
|
|
Feb 02
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.72%
|
$20,000
$2.06 P/Share
|
|
Feb 01
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.52%
|
$220,000
$22.87 P/Share
|
|
Feb 01
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.4%
|
$20,000
$2.06 P/Share
|
|
Jan 23
2023
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
3,500
-2.85%
|
$87,500
$25.01 P/Share
|
|
Jan 23
2023
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+2.77%
|
$7,000
$2.06 P/Share
|
|
Jan 23
2023
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
1,000
-2.25%
|
$25,000
$25.02 P/Share
|
|
Jan 19
2023
|
Sarah Aebersold Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
374
-0.84%
|
$8,228
$22.93 P/Share
|
|
Jan 19
2023
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
538
-1.2%
|
$11,836
$22.93 P/Share
|
|
Jan 19
2023
|
Roderick De Greef President and CEO |
BUY
Open market or private sale
|
Direct |
3,801
+8.65%
|
$87,423
$23.19 P/Share
|
|
Jan 18
2023
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.25%
|
$75,000
$25.04 P/Share
|
|
Jan 18
2023
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
6,500
-5.17%
|
$162,500
$25.04 P/Share
|
|
Jan 18
2023
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+4.91%
|
$13,000
$2.06 P/Share
|
|
Jan 11
2023
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
258
-0.53%
|
$5,418
$21.94 P/Share
|
|
Jan 04
2023
|
Roderick De Greef President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,647
+18.0%
|
-
|
|
Jan 04
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.91%
|
$180,000
$18.1 P/Share
|
|
Jan 04
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.85%
|
$20,000
$2.06 P/Share
|
|
Jan 03
2023
|
Rachel Ellingson Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,187
+24.84%
|
-
|
|
Jan 03
2023
|
Joydeep Goswami Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,187
+26.1%
|
-
|
|
Jan 03
2023
|
Timothy L. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,187
+36.43%
|
-
|
|
Jan 03
2023
|
Joseph C Schick Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,187
+24.36%
|
-
|
|
Jan 03
2023
|
Amy Du Ross Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,187
+26.44%
|
-
|
|
Jan 03
2023
|
Michael Rice |
BUY
Grant, award, or other acquisition
|
Direct |
99,038
+17.82%
|
-
|
|
Jan 03
2023
|
Troy Wichterman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,295
+30.29%
|
-
|
|
Jan 03
2023
|
Geraint Phillips SVP, Global Operations |
BUY
Grant, award, or other acquisition
|
Direct |
21,222
+26.26%
|
-
|
|
Jan 03
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,939
+7.11%
|
-
|
|
Jan 03
2023
|
Marcus Schulz Chief Revenue Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,733
+20.89%
|
-
|
|
Jan 03
2023
|
Karen A. Foster Chief Quality and Operations |
BUY
Grant, award, or other acquisition
|
Direct |
16,978
+11.98%
|
-
|
|
Jan 03
2023
|
Todd Berard Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,885
+9.06%
|
-
|
|
Jan 03
2023
|
Sarah Aebersold Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,450
+21.85%
|
-
|
|
Jan 03
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.91%
|
$180,000
$18.26 P/Share
|
|
Jan 03
2023
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.85%
|
$20,000
$2.06 P/Share
|
|
Dec 28
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
712
-0.28%
|
$11,392
$16.9 P/Share
|
|
Dec 28
2022
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
501
-0.46%
|
$8,016
$16.9 P/Share
|
|
Dec 28
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
898
-0.25%
|
$14,368
$16.9 P/Share
|
|
Dec 28
2022
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
605
-0.56%
|
$9,680
$16.9 P/Share
|
|
Dec 22
2022
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
528
-1.17%
|
$8,976
$17.55 P/Share
|
|
Nov 30
2022
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
33,905
-49.7%
|
$678,100
$20.59 P/Share
|
|
Nov 29
2022
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
1,500
-2.15%
|
$30,000
$20.2 P/Share
|
|
Nov 29
2022
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
307
-0.28%
|
$5,833
$19.93 P/Share
|
|
Nov 29
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
931
-0.26%
|
$17,689
$19.93 P/Share
|
|
Nov 29
2022
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
52
-0.12%
|
$988
$19.93 P/Share
|
|
Nov 29
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
436
-0.17%
|
$8,284
$19.93 P/Share
|
|
Nov 28
2022
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-6.48%
|
$210,000
$21.1 P/Share
|
|
Nov 23
2022
|
Michael Rice |
SELL
Bona fide gift
|
Direct |
2,750
-0.76%
|
-
|
|
Nov 23
2022
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
4,500
-5.34%
|
$94,500
$21.71 P/Share
|